“Effectiveness of Erythropoiesis-Stimulating Agent Therapy with Oral and Intravenous Iron Supplementation in Achieving Hemoglobin Targets in Stage 5 Chronic Kidney Disease Patients” (2026) JURNAL FARMASIMED (JFM), 9(1), pp. 499–507. doi:10.35451/jfm.v9i1.3691.